Dr. Joël Claveau
Dr. Joël Claveau is a dermatologist, specialized in the diagnosis and treatment of Melanoma and Skin Cancers, and an Associate Professor with the Department of Medicine at Laval University where he completed his Medical Study and Internal Medicine training. He did his residency in Dermatology at McGill University and subsequently worked at the Melanoma Clinic at the Royal Victoria Hospital in Montreal, Quebec. He is a diplomat of the American Board of Dermatology and is a member of a number of Medical Societies including the American Academy of Dermatology and the International Dermoscopy Society. He has received awards including
Honorary Member of La Société Française de Dermatologie, the Dermatologist’s Volunteer Award of the Canadian Dermatology Association (CDA) for his work on the prevention of skin cancers and the CDA
Symposium of the year at two occasions (Dermoscopy).
Since 1996, he has been the Director of the Melanoma and Skin Cancer Clinic at Le Centre Hospitalier Universitaire, Hôtel-Dieu de Québec, and worked in
Public Health for the province of Québec especially on the new Tanning Bed Legislation. He participated to the publication of papers in peer-review journals including work on melanoma, skin cancers and sunscreens. He is actively involved in a various Continuing Medical Education events and investigator in many clinical trials on advanced and metastatic melanoma.
Thursday NOV 24, 2022
Targeted Therapies for BRAF-mutant metastatic melanoma
- Review the latest clinical research updates in BRAF-mutant metastatic melanoma
- Discuss the current Canadian treatment paradigm, treatment sequencing, and the impact of evolving treatment strategies
- Acquire practical strategies to optimize targeted therapy treatment management
- Review the cutaneous side effects of targeted therapy used in cancer treatment
Saturday NOV 26, 2022
Adjuvant Therapy for High-Risk Melanoma
More than 8000 patients receive the diagnosis of melanoma in Canada each year. Although most of these patients are cured with an excision, those with high-risk melanoma are at increased risk for distant metastasis and death. We will be reviewing current adjuvant treatment options for those patients and the emerging role of adjuvant immunotherapy.